Trial Profile
Efficacy and safety of SGLT2 inhibitor, Ipragliflozin in type 2 diabetes patients.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2014
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms ESST2
- 03 Jul 2014 New trial record